Lessons from the  RAMPART  study—and which is the best route of administration of benzodiazepines in status epilepticus by Silbergleit, Robert et al.
Lessons from the RAMPART study—and which is the best
route of administration of benzodiazepines in status
epilepticus
*Robert Silbergleit, †Daniel Lowenstein, ‡Valerie Durkalski, §Robin Conwit, and on
behalf of theNETT Investigators
*Department of EmergencyMedicine, University of Michigan, AnnArbor, Michigan, U.S.A.; †Department of
Neurology, University of California San Francisco, San Francisco, California, U.S.A.; ‡Department of Public Health
Sciences, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, U.S.A.; and
§National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, U.S.A.
SUMMARY
Early treatment of prolonged seizures with ben-
zodiazepines given intravenously by paramedics in
the prehospital setting had been shown to be asso-
ciated with improved outcomes, but the compara-
tive efficacy and safety of an intramuscular (IM)
route, which is faster and consistently achievable,
was previously unknown. RAMPART (the Rapid
Anticonvulsant Medication Prior to Arrival Trial)
was a double-blind randomized clinical trial to
determine if the efficacy of intramuscular (IM) mi-
dazolam is noninferior by a margin of 10% to that
of intravenous (IV) lorazepam in patients treated
by paramedics for status epilepticus (SE). In chil-
dren and adults with >5 min of convulsions and
who are still seizing at paramedic arrival, midazo-
lam administered by IM autoinjector was noninfe-
rior to IV lorazepam on the primary efficacy
outcomewith comparable safety. Patients treated
with IM midazolam were more likely to have
stopped seizing at emergency department (ED)
arrival, without emergency medical services
(EMS) rescue therapy, and were less likely to
require any hospitalization or admission to an
intensive care unit. Lessons from the RAMPART
study’s findings and potential implications on clini-
cal practice, on the potential role of other routes
of administration, on the effect of timing of inter-
ventions, and on future clinical trials are discussed.
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Early treatment of status epilepticus (SE) by paramed-
ics reduces the number of patients with persistent sei-
zures on emergency department (ED) arrival and the
number admitted to the intensive care unit (ICU) for
refractory status (Alldredge et al., 2001). Traditionally,
diazepam has been the agent used most frequently by
emergency medical services (EMS) to treat patients with
seizures despite evidence that intravenous lorazepam
may be more effective. Lorazepam has proven impracti-
cal for EMS use because of its short shelf life without
refrigeration. More recently midazolam has been adopted
in a limited number of EMS systems because it is more
rapidly absorbed by intramuscular and transmucosal
routes than diazepam or lorazepam, and has excellent sta-
bility (Warden & Frederick, 2006). The safety and effi-
cacy of intramuscular midazolam, however, had not until
recently been studied in a randomized controlled trial,
and the optimal agent for prehospital treatment of SE
was unknown. In RAMPART (the Rapid Anticonvulsant
Medication Prior to Arrival Trial) we hypothesized that
in the prehospital treatment of SE, the efficacy of intra-
muscular (IM) midazolam would be noninferior to that of
intravenous (IV) lorazepam, as determined by the propor-
tion of subjects with termination of clinically evident sei-
zure at arrival in the ED after a single dose of study
medication and without use of rescue medication
(Silbergleit et al., 2012a).
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RAMPART was a double-blind randomized noninferi-
ority clinical trial of the efficacy of IM midazolam ver-
sus IV lorazepam in the prehospital treatment of SE by
paramedics (Durkalski et al., 2011; Silbergleit et al.,
2012a). The trial was conducted in the Neurological
Emergencies Treatment Trials (NETT) network, a multi-
disciplinary clinical trials infrastructure funded by the
National Institute of Neurological Disorders and Stroke
(NINDS). RAMPART involved >4,314 paramedics, 33
EMS agencies, and 79 receiving hospitals across the
United States.
Subjects enrolled in RAMPART were all adminis-
tered study medication by IM autoinjector followed by
rapid placement of a venous catheter and IV study
medication. All subjects received active treatment. In
half of the subjects the active treatment was in the IM
study medication and in half active treatment was in
the IV study medication. Children >40 kg and all
adults randomized to active IM therapy were treated
with 10 mg midazolam IM followed by IV placebo.
Children >40 kg and all adults randomized to IV active
therapy were treated with IM placebo followed by
4 mg lorazepam IV. The weight of children was esti-
mated from their length using a length-based weight-
estimation tape. Active therapy in children estimated to
be <40 kg was either 5 mg midazolam IM or 2 mg
lorazepam IV. Children estimated to be <13 kg were
not enrolled.
A specially designed study box incorporated a
voice recorder activated by opening the box. Study
personnel used the device to identify the following
events: IM treatment, IV access obtained, IV adminis-
tered, administration of any rescue treatments, when
and if convulsions are observed to stop, and whether
the subject is convulsing on arrival at the ED. The
recorders’ time code allowed each event to be time-
stamped. When starting an IV was difficult, medics
attempted placement for at least 10 minutes, or were
allowed to place an intraosseous (IO) line in lieu of
IV access. Rescue therapy, as dictated by local EMS
protocol, was used in subjects who were still convuls-
ing 10 min after the last study medication was
administered.
The study was conducted under 21 Code of Federal
Regulations 50.24, U.S. Food and Drug Administration
(FDA) regulations governing emergency clinical
research performed with exception from informed con-
sent (EFIC) (U.S. Government Printing Office via GPO
Access, 2005). The institutional review board (IRB) at
the coordinating center and at each site reviewed and
approved the trial. Each site IRB reviewed local com-
munity consultation and public disclosure activities.
Subjects or their legally authorized representatives were
notified about enrollment in the trial by the study team
as soon as possible, usually while the subject was still
in the ED, and were asked for their consent for contin-
ued data collection through the subject’s end of study
(Silbergleit et al., 2012b).
Results
Eight hundred ninety-three subjects were enrolled
over 19 months (Silbergleit et al., 2012a). Subjects
were well balanced between treatment groups on demo-
graphic and clinical characteristics, dose tier, history of
epilepsy, accuracy in diagnosis of status epilepticus
(versus a discharge diagnosis of seizure mimic or
pseudoseizure), and in the diagnosis of the underlying
cause of status epilepticus. Among subjects with a prior
history of epilepsy, status epilepticus was most com-
monly from noncompliance with, or withdrawal from,
anticonvulsant medication, but idiopathic precipitants
and other breakthrough seizures were also common.
Status epilepticus resulting from lowering of the seizure
threshold by identifiable acute comorbidities was much
less common.
Seizures were absent without rescue therapy at ED
arrival in 329 (73.4%) of 448 subjects allocated to
active IM treatment and in 282 (63.4%) of 445 allocated
to active IV treatment (difference: 10.1%, 95% confi-
dence interval [CI] 4.0%, 16.1%; p < 0.001 for noninfe-
riority and p < 0.001 for superiority). Among the 119
subjects in the IM group and the 163 in the IV group
that failed the primary outcome, 47 (39.5%) and 57
(35.0%), respectively, received rescue medications
and were not seizing on arrival, and 22 (18.5%) and
42 (25.8%) received rescue medications and were still
seizing on arrival.
The secondary and safety outcomes were consistent
with and reinforced the finding of noninferiority for
the primary outcome. In IM and IV treatment groups,
the frequency of endotracheal intubation (14.1% vs.
14.4%), recurrent seizures (11.4% vs. 10.6%), and other
predefined safety outcomes were similar by group. In
those admitted, the ICU and hospital length of stay did
not vary with treatment group, but the proportion of
subjects admitted was significantly lower in the IM
group (57.6%) as compared to the IV group (65.6,
p = 0.01).
Time interval data included those subjects meeting
the primary outcome in whom time of active treatment
and seizure cessation were captured (n = 317). Time to
administration of drug by the IM route was signifi-
cantly shorter than by the IV route, but the onset of
action (seizure termination) after IV administration was
shorter than after IM administration. The overall
interval until seizure termination was similar in both
groups.
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Lessons from the RAMPART Study
Intramuscular Midazolam Is
the Best Option for the
Prehospital Treatment of
Status Epilepticus
The superiority of IM midazolam over IV lorazepam
in RAMPART indicates that early administration of IM
midazolam is the best option for the prehospital treat-
ment of SE by paramedics. Although early administra-
tion of adequate doses of IV lorazepam is the preferred
initial treatment for SE in the emergency department
and other controlled clinical environments, it has limi-
tations that make it less preferable for use by EMS.
The need to rapidly establish IV access in a convulsing
patient may delay benzodiazepine administration in the
prehospital environment, and lorazepam’s short shelf
life out of refrigeration is not pragmatic for EMS use
(McMullan et al., 2013). The ability to use an IM route
with midazolam allowed more reliable and rapid
administration and ultimately led to better clinical out-
comes as reflected in lower rates of hospital admission,




Some EMS systems that use midazolam for the pre-
hospital treatment of SE use transmucosal routes of
administration (buccal, nasal, or rectal) as an alternative
to IM administration. Such routes are less invasive and
are potentially similarly rapid (McMullan et al., 2010).
Advocates for these routes were disappointed that
RAMPART did directly compare alternative nonintra-
venous routes of midazolam administration to
each other and to intravenous lorazepam. Based on
what is known about the pharmacodynamics of trans-
mucosal midazolam, the RAMPART investigators feel
that the differences among various nonintravenous
routes are likely to be small, and that the trial success-
fully answered the key question: whether a non-IV
route can be noninferior to an IV route. In the context
of status epilepticus, the clinical importance of avoid-
ing the invasiveness of an IM injection per se is
unclear, and there are potential limitations to each
nonintravenous route. These include the relatively low
concentrations of midazolam that are commercially
available for atomized administration, and that have
most often been studied in nasal administration, as well
as the occasional problem of seizing patients spitting or
blowing out medication during administration. How-
ever, we feel that the RAMPART results should be
taken to be generally supportive of nonintravenous
midazolam administration.
Implications for the Timing of
Interventions for Status
Epilepticus
With regard to mechanism, the time interval data in
RAMPART are consistent with the expectation that the
medication given by the IM route is administered more
rapidly after arrival than medication given IV, but that
the onset of action after IV administration is more rapid
than after IM administration. The administration time
saved by using the IM route appears to more than offset
the delay in onset of action. It is interesting to speculate
that the earlier administration in the IM group, of just a
few minutes, may have been enough of a difference to
drive the slight superiority of IM seen in the primary
outcomes.
Implications for Future
Clinical Trials in the
Emergency Treatment of Status
Epilepticus
Although RAMPART definitively identified the best
route of administration and optimal benzodiazepine for
initial treatment of seizures and status epilepticus, it
also suggests many opportunities and questions for
future investigation. Primary among these is recognition
that 26.5% had SE that remained refractory to ben-
zodiazepines at emergency department arrival. Identifi-
cation of the most effective second-line anticonvulsant
therapy for this population is thus a research priority.
Furthermore, these clinical data indicating that earlier
treatment may work synergistically to improve anticon-
vulsant efficacy, taken in combination with preclinical
animal data, suggest that future clinical trials should
examine collapsing or accelerating the traditional serial
progression of emergency treatments of SE, includ-
ing the possible use of additional agents in prehospital
treatment.
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